65,437 trials
Carcinoma, Renal Cell
Primary: Number of Subjects With Overall Confirmed Objective Response (OR) — 41 participants
Primary Focal Hyperhidrosis, Axilla
Primary: Percentage of Subjects That Report an HDSS Score of 1 or 2 at 30 Days. — 54; 89 Percentage of Participants — p=<0.001
Recurrent and/or Metastatic Head and Neck Cancer
Primary: Overall Survival — 11.1; 9.0 months — p=0.1403
Pain
Primary: Pain, Measured as Units on a Scale — 4.0; 4.8 units on scale, 0-5
Gastroesophageal Reflux Disease
Primary: Total Number of Reflux Episodes During 24 Hours — 59.4; 50.7; 44.3; 38.0 Episodes
Pain · HIV Infections · Peripheral Nervous System Diseases
Primary: The Primary Measure of Efficacy Was the Percent Change in the "Average Pain for the Past 24 Hours" Numeric Pain Rating Scale (NPRS) Score From Baseline During Weeks 2 to…
Osteomyelitis
Primary: Any Creatine Phosphokinase (CPK) Elevation > 500 Units Per Liter (U/L) — 4; 5; 2 Participants
Diabetic Macular Edema
Primary: Change in Central Subfield Thickening From Baseline Through 34 Weeks — -10; -47; -27; -16 microns — p=0.46
Neoplasms, Prostate
Primary: Number of Participants With Prostate Cancer (PCa) Progression [Restricted Crude Rate Analysis: Number of Participants With PCa Divided by Number of Participants in the…
Previously Untreated Metastatic Colorectal Cancer
Primary: Progression-free Survival (PFS) — 6.6; 8.2 months — p=0.0048
Psoriasis
Primary: Participants With a Status of Mild or Better on Physician Global Assessment at Month 12 — 166 Participants
Muscle Cramp
Primary: Change in Frequency of Leg Cramps — .99; .53 Cramps per week
HIV Infections
Primary: Ribavirin Maximum Plasma Concentration — 630.09; 496.71 ng/mL
Chronic Kidney Disease
Primary: Change in Endotoxin Activity — -.057 EA units
Idiopathic Pulmonary Fibrosis
Primary: Absolute Change in Percent Predicted Forced Vital Capacity(FVC) — -9; -10 Change in Percent Predicted FVC